ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly In Second Deal With Canadian Firm

by Michael McCoy
July 29, 2013 | APPEARED IN VOLUME 91, ISSUE 30

Eli Lilly & Co. has licensed worldwide rights to a small-molecule transcriptional regulator for the treatment of osteoarthritis to Transition Therapeutics. Toronto-based Transition says the drug, TT-601, has completed preclinical development and can enter the clinic next year. Under the agreement, Lilly has an option to reacquire rights to TT-601 after reviewing clinical results. The two firms struck a similar deal over TT-401, a diabetes drug candidate, in 2010. Last month Lilly exercised its option to reacquire that drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment